Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Activating EGFR Mutation”

137 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 137 results

Testing effectiveness (Phase 2)UnknownNCT02069418
What this trial is testing

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

Who this might be right for
Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer RecurrentNo EGFR Activating Mutation
University Hospital, Angers 80
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Not applicableAvailableNCT06761976
What this trial is testing

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Who this might be right for
Advanced Non-small Cell Lung CancerCancer
Bayer
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Testing effectiveness (Phase 2)Study completedNCT01221077
What this trial is testing

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Who this might be right for
NSCLCNon Small Cell Lung Cancer
Astellas Pharma Inc 88
Testing effectiveness (Phase 2)UnknownNCT04989322
What this trial is testing

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Who this might be right for
NsclcEGFR Activating MutationEGF-R Positive Non-Small Cell Lung Cancer+3 more
Dr Joanne CHIU 46
Large-scale testing (Phase 3)Looking for participantsNCT06452277
What this trial is testing

Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Bayer 555
Testing effectiveness (Phase 2)Study completedNCT01378962
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 50
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07685197
What this trial is testing

Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

Who this might be right for
NSCLCEGFR Activating MutationEGFR-TKI-resistant Non-Small Cell Lung Cancer+2 more
Zhou Chengzhi 100
Testing effectiveness (Phase 2)Ended earlyNCT02580708
What this trial is testing

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 7
Testing effectiveness (Phase 2)Study completedNCT01372384
What this trial is testing

Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 6
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Not applicableStudy completedNCT03137264
What this trial is testing

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 44
Testing effectiveness (Phase 2)Study completedNCT02976116
What this trial is testing

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Hutchison Medipharma Limited 50
Testing effectiveness (Phase 2)Ended earlyNCT02949843
What this trial is testing

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Who this might be right for
EGFR Activating MutationRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences 19
Testing effectiveness (Phase 2)Ended earlyNCT02095782
What this trial is testing

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 10
Testing effectiveness (Phase 2)Looking for participantsNCT06706076
What this trial is testing

BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
BlossomHill Therapeutics 675
Large-scale testing (Phase 3)Ended earlyNCT02326285
What this trial is testing

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB

Who this might be right for
Non-squamous Non-small Cell Lung Cancer Stage IINon-squamous Non-small Cell Lung Cancer Stage IIIANon-squamous Non-small Cell Lung Cancer Stage IIIB+2 more
AIO-Studien-gGmbH 1
Large-scale testing (Phase 3)Looking for participantsNCT05768490
What this trial is testing

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Who this might be right for
Brain MetastasesRadiotherapyEGFR Activating Mutation
Sun Yat-sen University 232
Next Page
480